Predict your next investment

HEALTHCARE | Drug Delivery
mobiustherapeutics.com

See what CB Insights has to offer

Stage

Loan | Alive

Total Raised

$7.86M

Last Raised

$250K | 2 yrs ago

About Mobius Therapeutics

Mobius Therapeutics is a commercial stage venture focused on ophthalmic surgery solutions. Its first product, Mitosol, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery. The glaucoma indication is in active commercialization; the pterygium and refractive indications are awaiting approval by the Food and Drug Administration.

Mobius Therapeutics Headquarter Location

4041 Forest Park Avenue

St. Louis, Missouri, 63108,

United States

314-615-6930

Latest Mobius Therapeutics News

Mobius Therapeutics™ Expands Professional Education And Support Activities

Jun 30, 2020

Mobius Therapeutics™ Expands Professional Education And Support Activities As COVID-19 Affects Surgical Routine, Mobius™ Expands Outreach to Providers Author: Jun 30, 2020 2:01 PM EDT ST. LOUIS, June 30, 2020 /PRNewswire/ -- Recognizing the effect that COVID-19 has had on the routine of its customer base, Mobius Therapeutics™, LLC ,the St. Louis-based makers of Mitosol® (mitomycin for solution) Kit for Ophthalmic Use , is renewing efforts and reassigning resources to support customer needs related to Continuing Education and Customer Support. "The routine of our customers and its caregivers has changed at its most fundamental level," said Ed Timm, CEO of Mobius Therapeutics™. "If Mobius™ is to maintain its mission of improved patient care and superior customer experience, we must change our routine to conform with the evolving needs of its customers." Mitosol® is the only FDA approved formulation of mitomycin-c bearing an ophthalmic indication. With room temperature storage and shelf life of up to 24 months, Mitosol® offers unique flexibility to providers, as its "shelf-ready" status permits on demand utility. "Mobius™ has implemented distance learning modules, facilitated by multiple teleconferencing platforms," Timm continued. "The need for product knowledge, procedural integration, and assisting sites in complying with new standards related to use of hazardous drugs remains relevant and undeterred. This initiative is best summarized by a single statement: We thank you, we are here for you, and we will be with you into the future." About Mobius Therapeutics, LLC: Mobius Therapeutics™ is a commercial stage venture focused upon perioperative sterile injectables used in ophthalmic surgery. Its first product, Mitosol ®, is the only FDA approved formulation of mitomycin-c bearing an ophthalmic indication. Mobius maintains an active sterile injectable product pipeline in varying stages of development. Please see full prescribing information at www.Mitosol.com . CONTACT: Ed TimmMobius Therapeutics, LLC+1 314-615-6932 Ed.Timm@MobiusTherapeutics.com   View original content to download multimedia: http://www.prnewswire.com/news-releases/mobius-therapeutics-expands-professional-education-and-support-activities-301086180.html SOURCE Mobius Therapeutics, LLC

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Mobius Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Mobius Therapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,238 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Mobius Therapeutics Patents

Mobius Therapeutics has filed 10 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/12/2014

11/27/2018

Diseases of the eye and adnexa, Carbon nanotubes, Catheters, Implants (medicine), Ophthalmology

Grant

Application Date

5/12/2014

Grant Date

11/27/2018

Title

Related Topics

Diseases of the eye and adnexa, Carbon nanotubes, Catheters, Implants (medicine), Ophthalmology

Status

Grant

Mobius Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Mobius Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.